Dimitris Voliotis
Chief Medical Officer
Welcome, everybody. Welcome to our second webinar. I am Dimitris Voliotis. I’m the Chief Medical Officer for Radiopharm and it is a great pleasure for me to have you with us either for the first time or if you’re already there last week, then welcome you back to, as said, our second webinars. I will do a very brief intro and a recap of last week and then lead into today’s topic and presentation. Today, we have Dr. David Ulmert from UCLA. Very happy to have him here. Thank you, David, again.
So last week, we had 2 presentations and a very nice discussion following. The first was — first presentation was by Dr. Oliver Sartor, second by David Piwnica-Worms. Dr. Sartor gave us an overview of the prostate cancer treatment landscape, the unmet medical needs and emerging new treatments, including, of course, radiotherapy such as the combination of radium-223 with enzalutamide and then more targeted approaches, of course, like PSMA, radiotherapeutics such as Pluvicto.
These treatments and in particular, of course, Pluvicto, have changed the landscape of prostate cancer treatment very significantly over the past years. Pluvicto has demonstrated efficacy in prostate cancer patients before and after chemotherapy with the vision — with the PSMA 4 and the VISION trial, respectively. And now also very recently in June in earlier stage of disease, in other words, in hormone-sensitive prostate cancer with the PSMAddition trial.
Following these important achievements, of course, considering that all patients have — that have received some form of PSMA targeting treatments will relapse. So it’s very clear that there is still a big medical need for new
#Radiopharm #Theranostics #Limited #Special #Call